Beta-Blocker "Depression": Myth vs. Modern Evidence
The old teaching that beta-blockers cause depression traces to decades-old case reports that modern meta-analyses haven't replicated — but it's exactly what's making a post-MI patient hesitate to take a drug proven to reduce his mortality.
H.O., a 55-year-old warehouse supervisor, suffered an anterior STEMI four days ago, was treated with primary PCI, and is now being discharged on the standard guideline-directed secondary-prevention regimen: dual antiplatelet therapy with aspirin and a P2Y12 inhibitor after his drug-eluting stent, a high-intensity statin, an ACE inhibitor, and a beta-blocker, which was started in hospital within the first day per guideline timing and carries an established mortality benefit after myocardial infarction. He has a history of two depressive episodes, in his thirties and again in his forties, both resolved with sertraline and off any psychiatric medication for the past five years with no recurrence.
When his cardiologist walked through that list at discharge counseling, H.O. stopped at the metoprolol he had already been taking for three days and raised a specific concern: his father, decades ago, was told by a doctor that his own beta-blocker was 'making him depressed,' and H.O. has carried that family story into his own care, asking directly whether taking a beta-blocker now could bring his depression back after five stable years. He has no other chronic illness and no depressive symptoms currently — his PHQ-9 today is 2.
The belief H.O. is describing has real historical roots — case reports and some older observational studies from the 1960s through 1980s suggested an association between beta-blockers, particularly the more lipophilic agents like propranolol that cross the blood-brain barrier more readily, and depressive symptoms. That hypothesis shaped clinical teaching for a generation. Modern evidence has not held up the strength of that original signal: several large meta-analyses and cohort studies over the past decade have found either no significant association or a much smaller one than earlier literature suggested, without clearly confirming the lipophilicity-based mechanism as clinically meaningful for the agents in routine cardiac use today. The team's task is addressing his specific, understandable fear with the actual current evidence, not dismissing it or over-conceding to an outdated teaching that current data doesn't support.
At the cardiac discharge-planning visit
I want to be clear about what's actually at stake if we skip this — beta-blocker therapy after an anterior MI has a real, well-established mortality benefit, and avoiding it based on a concern the modern evidence doesn't strongly support would be trading a proven cardiac benefit for a risk that hasn't held up under closer study.
The history behind his concern is real, which is worth acknowledging directly rather than brushing past — the original beta-blocker-depression hypothesis came from genuine case reports and older observational data, particularly around lipophilic agents crossing into the CNS more readily. What's changed is that larger, more rigorous modern studies haven't replicated a strong causal signal, and the lipophilicity mechanism itself hasn't been clearly confirmed as clinically meaningful for routine cardiac dosing.
That's a meaningfully different evidentiary picture than what shaped the teaching his father's doctor was likely working from decades ago, and it's worth explaining that shift explicitly rather than just asserting the drug is safe.
His own depression history is real and worth taking seriously on its own terms, separate from the beta-blocker question — five years in stable remission is meaningful, but any post-MI patient with a depression history benefits from proactive mood monitoring given how common post-cardiac-event depression is generally, regardless of which medications are involved. I'd frame this as routine monitoring given his history, not a beta-blocker-specific precaution.
Metoprolol succinate was continued at standard post-MI dosing alongside the rest of his secondary-prevention regimen — dual antiplatelet therapy, a high-intensity statin, and an ACE inhibitor — after a direct conversation walking H.O. through the difference between the older case-report-based teaching and the modern meta-analytic evidence, with routine PHQ-9 monitoring added at cardiac follow-up visits given his personal depression history. The team was explicit that his concern attached to one drug in a four-drug regimen, and that the antiplatelet component in particular is not negotiable on any timeline.
H.O. left the discharge visit specifically reassured that his concern had been taken seriously and explained, not dismissed — the team's explicit goal was correcting an outdated family narrative with current evidence, while still tracking his own real depression history through routine, non-alarmist monitoring going forward.